Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials

While current lymphoma therapies induce remission in most dogs, drug‐resistant relapse is common, creating a need for novel agents. Rabacfosadine (RAB), a double prodrug of the acyclic nucleotide phosphonate 9‐(2‐phosphonylmethoxyethel) guanine (PMEG), preferentially targets lymphoma cells with redu...

Descripción completa

Detalles Bibliográficos
Autores principales: Saba, Corey F., Clifford, Craig, Burgess, Kristine, Phillips, Brenda, Vail, David, Wright, Zachary, Curran, Katie, Fan, Timothy, Elmslie, Robyn, Post, Gerald, Thamm, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754483/
https://www.ncbi.nlm.nih.gov/pubmed/32346934
http://dx.doi.org/10.1111/vco.12605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754483/
https://www.ncbi.nlm.nih.gov/pubmed/32346934
http://dx.doi.org/10.1111/vco.12605

Ejemplares similares